article thumbnail

First patient receives new engineered mRNA epigenetic

European Pharmaceutical Review

revealed the first patient to be dosed with OTX-2002, the first programmable mRNA therapeutic for c-Myc (MYC) oncogene overexpression, which targets cancer cells while sparing healthy cells. Biotech firm Omega Therapeutics, Inc. The investigation is expected to enrol around 190 volunteers in the US, Asia and Europe.

article thumbnail

3 Ways to Use an Engineering Mindset to Optimize Patient Access Workflows

MedCity News

In a day of vast innovation, expansion, and acquisitions, an engineering mindset can bring a unique and effective approach to thinking across the system, evaluating the current and future state, standardizing on best practices, and considering upstream and downstream workflows.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Re-engineering proteins to develop novel immunotherapies

European Pharmaceutical Review

However, even as science advances, there remain patients who still need new treatment options. By re-engineering existing approaches that have already shown clinical promise, there is potential to bring further benefit to the patient community in its fight against cancer.

article thumbnail

Re-engineering Cancer Clinical Trials at Scale

MedCity News

Engineers see everything as a system, know how to design under constraints, and recognize the need for trade-offs. Adopting an engineering mindset in oncology research can fix all the broken constituent processes like patient enrollment to systematize clinical trials.

article thumbnail

Novome gets $43.5M boost for its engineered microbiome therapies

MedCity News

Novome Biotechnologies — a biotech that CEO Blake Wise says is only company to pursue engineered cell therapy with microbes for the treatment of chronic diseases — raised $43.5 million in Series B funds.

article thumbnail

CapstanTx secures $165 million to deliver precise in vivo cell engineering

pharmaphorum

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering technology. The post CapstanTx secures $165 million to deliver precise in vivo cell engineering appeared first on.

article thumbnail

Driving the UK’s “innovation engine” for novel AMR therapeutics

European Pharmaceutical Review

SMEs and biotechs in [the AMR therapeutics] space really are the innovation engine… [particularly for] novel classes” Summarising this point, she declared that “SMEs and biotechs in [the AMR therapeutics] space really are the innovation engine… [particularly for] novel classes.” References Kraychete G, Bonelli R, Picão R.